JAMA Psychiatry:注意缺陷多动障碍治疗药物可改善患者学习成绩

2017-06-30 zhangfan MedSci原创

对于处于升学期的注意缺陷多动障碍患者,服用相应的治疗药物可以提高考试成绩。药物有助于改善注意缺陷多动障碍患者学业

注意缺陷多动障碍(ADHD)患者其学业往往存在较大困难。药物治疗有助于缓解注意缺陷多动障碍症状,但对患者学业的影响尚不清楚。近日研究人员考察了ADHD药物治疗与患者高等教育入学考试成绩之间的关系。

研究人员考察了2006-13年间61640名ADHD患者资料,研究人员从瑞典国家药物登记数据库以及瑞典学校能力倾向测验数据库中获得患者药物治疗以及成绩记录,以比较患者服用ADHD药物前后测试成绩差异。

研究共包含930名患者资料,其中男性493人,平均年龄22.2岁。患者共参与了2524项考试并间歇性使用ADHD药物。多因素调整后发现,使用药物相比于未使用药物,患者考试成绩提高4.8分(95% CI, 2.26-7.34;P<0.001)。敏感性分析发现,ADHD药物使用和测试分数提高之间存在相似关联。

研究认为,对于处于升学期的注意缺陷多动障碍患者,服用相应的治疗药物可以提高考试成绩。药物有助于改善注意缺陷多动障碍患者学业。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2079549, encodeId=2c1520e954992, content=<a href='/topic/show?id=df77454e987' target=_blank style='color:#2F92EE;'>#学习成绩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45479, encryptionId=df77454e987, topicName=学习成绩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 18 09:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792061, encodeId=ba9f1e92061f9, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Jul 03 20:00:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968834, encodeId=cc03196883466, content=<a href='/topic/show?id=01be430e1c3' target=_blank style='color:#2F92EE;'>#多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43071, encryptionId=01be430e1c3, topicName=多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat May 12 10:00:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980798, encodeId=543f1980e98cb, content=<a href='/topic/show?id=46be6501625' target=_blank style='color:#2F92EE;'>#注意缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65016, encryptionId=46be6501625, topicName=注意缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Thu Dec 07 20:00:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921684, encodeId=39061921684e7, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu May 03 08:00:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369980, encodeId=05d1136998060, content=<a href='/topic/show?id=b6e76501e50' target=_blank style='color:#2F92EE;'>#注意缺陷多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65017, encryptionId=b6e76501e50, topicName=注意缺陷多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sun Jul 02 05:00:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217099, encodeId=442f21e09939, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Fri Jun 30 14:11:00 CST 2017, time=2017-06-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2079549, encodeId=2c1520e954992, content=<a href='/topic/show?id=df77454e987' target=_blank style='color:#2F92EE;'>#学习成绩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45479, encryptionId=df77454e987, topicName=学习成绩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 18 09:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792061, encodeId=ba9f1e92061f9, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Jul 03 20:00:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968834, encodeId=cc03196883466, content=<a href='/topic/show?id=01be430e1c3' target=_blank style='color:#2F92EE;'>#多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43071, encryptionId=01be430e1c3, topicName=多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat May 12 10:00:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980798, encodeId=543f1980e98cb, content=<a href='/topic/show?id=46be6501625' target=_blank style='color:#2F92EE;'>#注意缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65016, encryptionId=46be6501625, topicName=注意缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Thu Dec 07 20:00:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921684, encodeId=39061921684e7, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu May 03 08:00:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369980, encodeId=05d1136998060, content=<a href='/topic/show?id=b6e76501e50' target=_blank style='color:#2F92EE;'>#注意缺陷多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65017, encryptionId=b6e76501e50, topicName=注意缺陷多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sun Jul 02 05:00:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217099, encodeId=442f21e09939, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Fri Jun 30 14:11:00 CST 2017, time=2017-06-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2079549, encodeId=2c1520e954992, content=<a href='/topic/show?id=df77454e987' target=_blank style='color:#2F92EE;'>#学习成绩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45479, encryptionId=df77454e987, topicName=学习成绩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 18 09:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792061, encodeId=ba9f1e92061f9, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Jul 03 20:00:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968834, encodeId=cc03196883466, content=<a href='/topic/show?id=01be430e1c3' target=_blank style='color:#2F92EE;'>#多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43071, encryptionId=01be430e1c3, topicName=多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat May 12 10:00:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980798, encodeId=543f1980e98cb, content=<a href='/topic/show?id=46be6501625' target=_blank style='color:#2F92EE;'>#注意缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65016, encryptionId=46be6501625, topicName=注意缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Thu Dec 07 20:00:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921684, encodeId=39061921684e7, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu May 03 08:00:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369980, encodeId=05d1136998060, content=<a href='/topic/show?id=b6e76501e50' target=_blank style='color:#2F92EE;'>#注意缺陷多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65017, encryptionId=b6e76501e50, topicName=注意缺陷多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sun Jul 02 05:00:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217099, encodeId=442f21e09939, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Fri Jun 30 14:11:00 CST 2017, time=2017-06-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2079549, encodeId=2c1520e954992, content=<a href='/topic/show?id=df77454e987' target=_blank style='color:#2F92EE;'>#学习成绩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45479, encryptionId=df77454e987, topicName=学习成绩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 18 09:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792061, encodeId=ba9f1e92061f9, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Jul 03 20:00:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968834, encodeId=cc03196883466, content=<a href='/topic/show?id=01be430e1c3' target=_blank style='color:#2F92EE;'>#多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43071, encryptionId=01be430e1c3, topicName=多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat May 12 10:00:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980798, encodeId=543f1980e98cb, content=<a href='/topic/show?id=46be6501625' target=_blank style='color:#2F92EE;'>#注意缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65016, encryptionId=46be6501625, topicName=注意缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Thu Dec 07 20:00:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921684, encodeId=39061921684e7, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu May 03 08:00:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369980, encodeId=05d1136998060, content=<a href='/topic/show?id=b6e76501e50' target=_blank style='color:#2F92EE;'>#注意缺陷多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65017, encryptionId=b6e76501e50, topicName=注意缺陷多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sun Jul 02 05:00:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217099, encodeId=442f21e09939, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Fri Jun 30 14:11:00 CST 2017, time=2017-06-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2079549, encodeId=2c1520e954992, content=<a href='/topic/show?id=df77454e987' target=_blank style='color:#2F92EE;'>#学习成绩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45479, encryptionId=df77454e987, topicName=学习成绩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 18 09:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792061, encodeId=ba9f1e92061f9, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Jul 03 20:00:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968834, encodeId=cc03196883466, content=<a href='/topic/show?id=01be430e1c3' target=_blank style='color:#2F92EE;'>#多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43071, encryptionId=01be430e1c3, topicName=多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat May 12 10:00:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980798, encodeId=543f1980e98cb, content=<a href='/topic/show?id=46be6501625' target=_blank style='color:#2F92EE;'>#注意缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65016, encryptionId=46be6501625, topicName=注意缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Thu Dec 07 20:00:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921684, encodeId=39061921684e7, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu May 03 08:00:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369980, encodeId=05d1136998060, content=<a href='/topic/show?id=b6e76501e50' target=_blank style='color:#2F92EE;'>#注意缺陷多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65017, encryptionId=b6e76501e50, topicName=注意缺陷多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sun Jul 02 05:00:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217099, encodeId=442f21e09939, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Fri Jun 30 14:11:00 CST 2017, time=2017-06-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2079549, encodeId=2c1520e954992, content=<a href='/topic/show?id=df77454e987' target=_blank style='color:#2F92EE;'>#学习成绩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45479, encryptionId=df77454e987, topicName=学习成绩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 18 09:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792061, encodeId=ba9f1e92061f9, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Jul 03 20:00:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968834, encodeId=cc03196883466, content=<a href='/topic/show?id=01be430e1c3' target=_blank style='color:#2F92EE;'>#多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43071, encryptionId=01be430e1c3, topicName=多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat May 12 10:00:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980798, encodeId=543f1980e98cb, content=<a href='/topic/show?id=46be6501625' target=_blank style='color:#2F92EE;'>#注意缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65016, encryptionId=46be6501625, topicName=注意缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Thu Dec 07 20:00:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921684, encodeId=39061921684e7, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu May 03 08:00:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369980, encodeId=05d1136998060, content=<a href='/topic/show?id=b6e76501e50' target=_blank style='color:#2F92EE;'>#注意缺陷多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65017, encryptionId=b6e76501e50, topicName=注意缺陷多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sun Jul 02 05:00:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217099, encodeId=442f21e09939, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Fri Jun 30 14:11:00 CST 2017, time=2017-06-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2079549, encodeId=2c1520e954992, content=<a href='/topic/show?id=df77454e987' target=_blank style='color:#2F92EE;'>#学习成绩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45479, encryptionId=df77454e987, topicName=学习成绩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 18 09:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792061, encodeId=ba9f1e92061f9, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Jul 03 20:00:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968834, encodeId=cc03196883466, content=<a href='/topic/show?id=01be430e1c3' target=_blank style='color:#2F92EE;'>#多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43071, encryptionId=01be430e1c3, topicName=多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat May 12 10:00:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980798, encodeId=543f1980e98cb, content=<a href='/topic/show?id=46be6501625' target=_blank style='color:#2F92EE;'>#注意缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65016, encryptionId=46be6501625, topicName=注意缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Thu Dec 07 20:00:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921684, encodeId=39061921684e7, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu May 03 08:00:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369980, encodeId=05d1136998060, content=<a href='/topic/show?id=b6e76501e50' target=_blank style='color:#2F92EE;'>#注意缺陷多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65017, encryptionId=b6e76501e50, topicName=注意缺陷多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sun Jul 02 05:00:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217099, encodeId=442f21e09939, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Fri Jun 30 14:11:00 CST 2017, time=2017-06-30, status=1, ipAttribution=)]
    2017-06-30 圣艮山

    学习了不少事情!

    0

相关资讯

BMJ:哌甲酯治疗儿童及青少年注意缺陷多动障碍(ADHD)是否增加心血管风险?

该研究的目的是确定哌甲酯治疗儿童及青少年注意缺陷多动障碍(ADHD)是否与心血管事件相关。原始出处:Ju-Young Shin,Elizabeth E Roughead,Byung-Joo Park,et al.Cardiovascular safety of methylphenidate among children and young people with attention-defici

VISION RES :无意识眼动或为ADHD简易诊断指标

来自以色列特拉维夫大学的研究人员及其合作小组在Vision Research杂志上发表的研究成果揭示,无意识眼动提示罹患注意缺陷多动障碍(ADHD)的可能性,同时也证明了治疗用药物确有疗效。该成果将为医生提供一种客观的手段来诊断ADHD。 根据美国疾病预防与控制中心(CDC)的数据,ADHD是小孩子最常见的行为失常疾病,而且也最容易被误诊。然而,目前依然没有可靠的生理指标作为诊断标准。

BMJ:利他林治疗儿童和青少年注意缺陷多动障碍(ADHD)研究(荟萃分析)

哌醋甲酯(哌甲酯、利他林)对于治疗儿童和青少年注意缺陷多动障碍(ADHD)是有益还是有害?

JAMA Pediatr:青少年注意缺陷多动障碍与交通事故风险

注意缺陷多动障碍会影响青少年患者操控机动车的能力,导致交通事故风险增加

ADHD治疗,如何降低药物滥用风险?

一项新的研究结果显示,父母通常经常担心他们的孩子选择服用兴奋剂来治疗注意缺陷多动障碍(ADHD),他们认为这增加了物质滥用风险。目前,一项令人惊奇的新研究发现,当人们很早的服用或者长时间服用利他林和阿得拉药物时,药物滥用风险降低了。“最值得注意的是,对于那些很早开始服用,或服用兴奋剂类药物时间较长的ADHD青年人群来说,他们的药物滥用风险与普通人群是一样的,”该研究的负责人 Sean Esteba

J Behavioral &Brain Sci:注意缺陷多动障碍治疗药物需慎用

注意缺陷障碍(伴多动)症(ADHD)出现在童年,会持续到成年时期。这种疾病表现为注意力不集中、多动症、过度的表现欲和无法保持专注,或无法长时间集中注意力。哌甲酯(Methylphenidate,MPD)俗称利他林(Ritalin),是治疗ADHD的常用治疗药物之一,用于延长(注意力集中的)时间,它作为认知增强和娱乐物质也非常流行。 长期使用MPD,受体和突触连接过剩,“修剪”神经